Last reviewed · How we verify

Group 3 in Part B and Part C (group-3-in-part-b-and-part-c)

Pfizer Inc. · discontinued

Dose 4 KAN-101 Intravenous (IV) infusion

This response cannot be completed because the drug name, FDA mechanism text, and approved indications are missing from the provided information. Group 3 in Part B and Part C are regulatory classification categories, but specific drug identity and clinical data are required to generate an accurate summary.

At a glance

Generic namegroup-3-in-part-b-and-part-c
SponsorPfizer Inc.
Drug classDose 4 KAN-101 Intravenous (IV) infusion
Therapeutic areaInfectious Disease
Phasediscontinued

Mechanism of action

The information provided references 'Group 3 in Part B and Part C' which are regulatory framework categories rather than a specific drug. To create an accurate AI summary, one-sentence explanation, and detailed explanation, I would need: (1) the actual drug name, (2) the complete FDA mechanism text describing how the drug works, and (3) the specific approved indications. Group 3 classifications vary by regulatory context and don't have inherent meaning without the associated drug data. Please provide the missing drug information to generate the requested JSON with accurate medical content.

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: